Want to see TSE:NARA full AI Analyst Report?
PanGenomic Health, Inc. Class A (NARA) Ratios
PanGenomic Health, Inc. Class A Ratios
TSE:NARA's free cash flow for Q2 2026 was $-265.59K. For the 2026 fiscal year, TSE:NARA's free cash flow was increased by $0.00 and operating cash flow was $-265.59K. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Jun 25 | Jun 24 | Mar 23 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.07 | 0.02 | 0.03 | 0.67 | 4.99 |
| Quick Ratio | 0.07 | 0.02 | 0.03 | 0.67 | 4.99 |
| Cash Ratio | 0.02 | 0.00 | 0.01 | 0.12 | 4.03 |
| Solvency Ratio | -1.46 | -0.00 | -1.34 | -28.28 | -7.92 |
| Operating Cash Flow Ratio | -0.80 | -0.02 | -0.71 | -3.87 | -3.17 |
| Short-Term Operating Cash Flow Coverage | -8.84 | 0.00 | -1.63 | -27.34 | 0.00 |
| Net Current Asset Value | $ -2.19M | $ -2.41M | $ -2.16M | $ -234.88K | $ 1.34M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 1.32 | 0.00 | 13.50 | 0.20 | 0.00 |
| Debt-to-Equity Ratio | -0.10 | 0.00 | -0.45 | -0.47 | 0.00 |
| Debt-to-Capital Ratio | -0.11 | 0.00 | -0.82 | -0.90 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.07 | -0.02 | -0.03 | -2.34 | 1.15 |
| Debt Service Coverage Ratio | -15.77 | -0.02 | -2.69 | -115.63 | -344.68 |
| Interest Coverage Ratio | -835.72 | -0.02 | -61.58 | -2776.03 | -345.83 |
| Debt to Market Cap | 0.03 | 0.00 | 0.10 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.01 | 14.40 | 0.10 | 0.02 | 0.00 |
| Net Debt to EBITDA | -0.05 | 1.18 | -0.35 | -0.00 | 1.59 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 169.65% | 100.09% |
| EBT Per EBIT | 100.29% | 333.89% | 109.63% | 329.57% | 310.66% |
| Return on Assets (ROA) | -2132.54% | -9.71% | -4159.20% | -4036.16% | -102.91% |
| Return on Equity (ROE) | 156.79% | 0.16% | 138.62% | 9459.33% | -118.25% |
| Return on Capital Employed (ROCE) | 156.33% | 0.05% | 126.45% | 1691.87% | -38.03% |
| Return on Invested Capital (ROIC) | 173.17% | 0.05% | 229.84% | 3211.05% | -38.03% |
| Return on Tangible Assets | -2132.54% | -9.71% | -4159.20% | -4036.16% | -153.56% |
| Earnings Yield | -40.47% | -582.92% | -29.77% | -27.50% | -10.73% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.85 | 0.03 | 0.01 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -571134.33 | -705742.82 | -427.89 | -12313.08 | -29308.80 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 571134.33 | 705742.82 | 427.89 | 12313.08 | 29308.80 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.10 | -12.50 | -0.16 | -0.51 | -0.54 |
| Free Cash Flow Per Share | -0.10 | -12.50 | -0.16 | -0.51 | -0.54 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -499.07 | -463.37 | -155.45 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -499.07 | -463.37 | -155.45 |
| Operating Cash Flow Coverage Ratio | -8.84 | 0.00 | -1.63 | -27.34 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -22.19% | -8929.03% | -15.74% | -3.77% | -4.31% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.42 | -0.17 | -3.36 | -3.64 | -9.32 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -3.87 | -0.00 | -4.66 | -343.92 | 11.02 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.51 | -0.01 | -6.35 | -26.53 | -23.18 |
| Price-to-Operating Cash Flow Ratio | -4.51 | -0.01 | -6.37 | -26.59 | -23.33 |
| Price-to-Earnings Growth (PEG) Ratio | 0.03 | -0.00 | 0.04 | -0.06 | -0.02 |
| Enterprise Value Multiple | -2.53 | 0.59 | -4.03 | -20.75 | -27.57 |
| Enterprise Value | 8.65M | -654 | 10.94M | 73.99M | 23.36M |
| EV to EBITDA | -2.53 | 0.59 | -4.03 | -20.75 | -27.57 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -4.60 | 0.01 | -6.96 | -26.53 | -21.92 |
| EV to Operating Cash Flow | -4.60 | 0.01 | -6.97 | -26.59 | -22.06 |
| Tangible Book Value Per Share | -0.12 | -516.19 | -0.21 | -0.04 | 0.70 |
| Shareholders’ Equity Per Share | -0.12 | -516.19 | -0.21 | -0.04 | 1.13 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | -0.70 | -0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.19 | -0.82 | -0.30 | -3.71 | -1.34 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.70 | 1.00 |
| Interest Burden | 1.00 | 3.42 | 1.09 | 3.35 | 3.12 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.55 | 0.02 | 0.53 | 0.23 | 0.40 |
Currency in CAD